Immuneering reported updated phase IIa data showing a 64% overall survival rate at 12 months for atebimetinib combined with modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer, compared with a historical external benchmark. The company said median overall survival remained unreached at the data cutoff and highlighted progression‑free survival separation versus historical controls. Immuneering provided an updated safety and OS analysis ahead of a planned pivotal trial, noting the next step is a randomized, ~510‑patient phase III study with overall survival as the primary endpoint to start in mid‑2026. The company emphasized that the phase IIa findings support selecting the MEK inhibitor dose and moving into registrational testing. Analysts flagged the need for randomized data versus standard of care, but noted the survival signal and upcoming expanded‑cohort readouts could materially de‑risk a pivotal program in a disease with historically poor outcomes.